Aspirin Often Added to Warfarin in AF Without CAD, Despite Bleeding Risk

July 19, 2013

DALLAS, TX — More than a third of patients with atrial fibrillation (AF) who were on oral anticoagulation in a large cohort study were also taking aspirin[1]. Although most on aspirin also had some sort of vascular disease, the remaining 39% had no history of PCI, MI, cerebrovascular events, or other clinical cardiovascular disease that might justify aspirin use under the guidelines.

In the evidence base and in the guidelines, it's a gray area whether patients with both AF and CV disease should get aspirin along with their oral anticoagulation, senior author Dr Eric D Peterson (Duke Clinical Research Institute, Durham, NC) explained for heartwire . Oral anticoagulation in the current analysis essentially meant warfarin.

"We anticipated that some of them would get [aspirin] and some would not, and that's what we saw" in the analysis of >7000 patients with AF receiving oral anticoagulation who were participants in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). But there was no apparent pattern to help explain the variation.

Also, about 40% of the patients with AF and no CV disease were also taking aspirin on top of oral anticoagulation, despite "no indication, that we know of, for aspirin," according to Peterson. "We're still struggling a bit to understand why so many were on aspirin.

"In general, if I see a patient in my clinic who has only atrial fibrillation and no other risk factors, they should not be on aspirin," Peterson said. "Because I know for sure their risk of bleeding is going to be one and a half times what it was before."

Even among those with vascular disease, he said, no consistent pattern emerged that seemed to explain variation in aspirin use. It apparently wasn't based on differences in bleeding risk, as distribution of ATRIA bleeding-risk scores for those on and not on aspirin weren't significantly different; for example, 17% in both groups had scores indicating the highest bleeding risk.

The study was published online July 16, 2013 in Circulation, with first author Dr Benjamin A Steinberg (Duke University Medical Center, Durham, NC).

In the analysis looking at bleeding, hospitalization, ischemic events, and mortality at six months in 7347 AF patients receiving oral anticoagulation at 174 sites in the US, 35% were also taking aspirin. The daily dosage was 81 mg in 85% of patients and 325 mg in nearly all the rest.

Hazard Ratio* (95% CI) for End Points at Six Months, Oral Anticoagulation With vs Without Aspirin, in ORBIT-AF

End point HR (95% CI) p
Major bleeding 1.53 (1.20–1.96) 0.0006
Nuisance bleeding 1.09 (0.96–1.25) 0.18
All-cause hospitalization 1.08 (1.00–1.17) 0.06
Hospitalization for bleeding 1.52 (1.17–1.97) 0.002

*Propensity-adjusted for baseline age, weight, creatinine clearance, diastolic blood pressure, sex, hyperlipidemia, liver disease, hypertension, diabetes, smoking, thyroid disease, prior gastrointestinal bleed, history of stroke or transient ischemic attack, history of CAD, peripheral arterial disease, CABG, PCI, drug-eluting-stent use, prior antiarrhythmic drug therapy, prior interventional therapy for AF, renal disease, valvular disease, prior valve replacement or repair, level of education, ECG evidence of LV hypertrophy, provider specialty, type of AF, and region

Aspirin use had no apparent effect on ischemic events (although end points were few) and gastrointestinal bleeding, but the opposite was true for major bleeds overall and hospitalization for bleeding.

Peterson said the risks of adding aspirin to warfarin or, potentially, the newer generation of oral anticoagulants, are widely underestimated. He sees several possible explanations for rampant aspirin overuse.

Many individuals are taking aspirin for primary prevention, a once-justifiable practice that has since been largely discredited, yet many are still on it, he observed. And "in my own clinical practice, I watch patients who come into the hospital to rule out chest pain get put on aspirin," he said. Or "a lot of patients who come in with atrial fibrillation have some degree of cardiac symptoms, so they get started on aspirin; subsequently, a stress test or other [test] rules out vascular disease, but aspirin remains in their formulary--nothing ever gets dropped."

Peterson said the risks of combining aspirin with oral anticoagulation are likely to be similar whether it's warfarin or the newer oral agents apixaban (Eliquis, Pfizer/Bristol-Myers Squibb), dabigatran (Pradaxa, Boehringer Ingelheim), and rivaroxaban (Xarelto, Bayer/Johnson & Johnson).

In an accompanying editorial[2], Drs Carlo Patrono and Felicita Andreotti (Istituto di Farmacologia, Università Cattolica del S Cuore, Rome, Italy) note that ORBIT-AF highlights "the need for an adequately sized randomized trial comparing oral anticoagulation alone against oral anticoagulation and low-dose aspirin in patients with atherothrombotic vascular disease and nonvalvular AF at moderate to high thromboembolic risk." The question wasn't settled either by the WOEST or WARIS 2 trials, they write.

The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, they note, "is currently testing the efficacy and safety of anticoagulation alone with rivaroxaban against aspirin monotherapy or the combination of aspirin and low-dose anticoagulation in about 20 000 patients with coronary or peripheral artery disease followed for approximately five years, reflecting the continued interest and need for very large trials in the area of combined antiplatelet and anticoagulant therapy."

The ORBIT-AF registry is sponsored by Janssen Scientific Affairs. Steinberg discloses receiving "educational support" from Medtronic. Peterson discloses receiving research grant support from Eli Lilly, Janssen Pharmaceuticals, and the American Heart Association; and consultant/advisory-board support from Boehringer Ingelheim, Bristol-Myers Squibb, Janssen Pharmaceuticals, Pfizer, and Genentech. Disclosures for the coauthors are listed in the paper. Patrono discloses receiving consulting and speaker fees from AstraZeneca, Bayer AG, Eli Lilly, and Merck. Andreotti discloses receiving consulting and speaker fees from Bayer AG, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, and Eli Lilly.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.